Greenbrook TMS FY 2023 revenue up 10% to $73.8M; net loss narrows to $49.3M

Greenbrook TMS Inc.

2024-Q1 EPS reported -$0.32 revenue$5,563,038

Revenue $73.8M, +10% YoY; regional operating loss improved 56% to $2.7M.
Net loss $49.3M vs $88.3M; loss per share $1.25 diluted (prior $3.77).
Restructuring: closed 53 centers, achieved $23M annual cost savings target, $1M charges.
Expanded Spravato to 82 centers; launched medication management pilot at 9 centers.
Company changed to domestic issuer; restated quarterly financials from IFRS to US GAAP.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Greenbrook TMS Inc. reported the fiscal year ended December 31, 2023 results: revenue $73.8 million, net income $49.3 million, EPS $(1.25).

Period: the fiscal year ended December 31, 2023
Revenue: $73.8 million
Net income: $49.3 million
EPS: $(1.25)
Result: reported results

Exact text from the filing

are in United States dollars, unless otherwise stated. FISCAL 2023 OPERATIONAL AND FINANCIAL HIGHLIGHTS · Consolidated revenue increased by 10% in Fiscal 2023 to a record $73.8 million, up $7 million as compared to the fiscal year ended December 31, 2022 (“ Fiscal 2022 ”) despite the closure of 53 treatment centers (approximately 29% of active treatment

View on SEC.gov

316 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-052141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.